The PI3K/Akt Pathway in Tumors of endocrine Tissues

被引:101
作者
Robbins, Helen Louise [1 ]
Hague, Angela [2 ]
机构
[1] Univ Hosp Coventry & Warwickshire, Dept Gen Surg, Coventry, W Midlands, England
[2] Univ Bristol, Sch Cellular & Mol Med, Sch Oral & Dent Sci, Bristol, Avon, England
来源
FRONTIERS IN ENDOCRINOLOGY | 2016年 / 6卷
关键词
thyroid tumors; parathyroid tumors; pituitary tumors; adrenocortical carcinoma; phaeochromocytoma; neuroblastoma; gastroenteropancreatic neuroendocrine tumors; Akt/PKB kinases; GROWTH-FACTOR RECEPTOR; THYROID-CANCER CELLS; MORPHOPROTEOMICS DEMONSTRATES ACTIVATION; AKT ACTIVATION; PHOSPHATIDYLINOSITOL; 3-KINASE/AKT; MAMMALIAN TARGET; MTOR PATHWAY; ADRENOCORTICAL CARCINOMA; NEUROENDOCRINE TUMORS; PITUITARY-ADENOMAS;
D O I
10.3389/fendo.2015.00188
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a key driver in carcinogenesis. Defects in this pathway in human cancer syndromes such as Cowden's disease and Multiple Endocrine Neoplasia result in tumors of endocrine tissues, highlighting its importance in these cancer types. This review explores the growing evidence from multiple animal and in vitro models and from analysis of human tumors for the involvement of this pathway in the following: thyroid carcinoma subtypes, parathyroid carcinoma, pituitary tumors, adrenocortical carcinoma, phaeochromocytoma, neuroblastoma, and gastroenteropancreatic neuroendocrine tumors. While data are not always consistent, immunohistochemistry performed on human tumor tissue has been used alongside other techniques to demonstrate Akt overactivation. We review active Akt as a potential prognostic marker and the PI3K pathway as a therapeutic target in endocrine neoplasia.
引用
收藏
页数:22
相关论文
共 50 条
[21]   Investigation of EGFR/pi3k/Akt signaling pathway in seminomas [J].
Guerra, F. ;
Quintana, S. ;
Giustina, S. ;
Mendeluk, G. ;
Jufe, L. ;
Avagnina, M. A. ;
Diaz, L. B. ;
Palaoro, L. A. .
BIOTECHNIC & HISTOCHEMISTRY, 2021, 96 (02) :125-137
[22]   The relation between PI3K/AKT signalling pathway and cancer [J].
Noorolyai, Saeed ;
Shajari, Neda ;
Baghbani, Elham ;
Sadreddini, Sanam ;
Baradaran, Behzad .
GENE, 2019, 698 :120-128
[23]   The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma [J].
Fulda, S. .
CURRENT CANCER DRUG TARGETS, 2009, 9 (06) :729-737
[24]   Drugging the PI3K/AKT/mTOR Pathway in ER plus Breast Cancer [J].
Alves, Carla L. ;
Ditzel, Henrik J. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
[25]   Targeting the PI3K/AKT/mTOR pathway in ovarian cancer [J].
Musa, Fernanda ;
Schneider, Robert .
TRANSLATIONAL CANCER RESEARCH, 2015, 4 (01) :97-106
[26]   MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer [J].
Hu, Mingli ;
Zhu, Shixuan ;
Xiong, Shengwei ;
Xue, Xingxing ;
Zhou, Xiaodong .
ONCOLOGY REPORTS, 2019, 41 (03) :1439-1454
[27]   The PI3K Pathway in Human Disease [J].
Fruman, David A. ;
Chiu, Honyin ;
Hopkins, Benjamin D. ;
Bagrodia, Shubha ;
Cantley, Lewis C. ;
Abraham, Robert T. .
CELL, 2017, 170 (04) :605-635
[28]   Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway [J].
Blanco, Elvin ;
Sangai, Takafumi ;
Wu, Suhong ;
Hsiao, Angela ;
Ruiz-Esparza, Guillermo U. ;
Gonzalez-Delgado, Carlos A. ;
Cara, Francisca E. ;
Granados-Principal, Sergio ;
Evans, Kurt W. ;
Akcakanat, Argun ;
Wang, Ying ;
Do, Kim-Anh ;
Meric-Bernstam, Funda ;
Ferrari, Mauro .
MOLECULAR THERAPY, 2014, 22 (07) :1310-1319
[29]   Stage-dependent expression of PI3K/Akt-pathway genes in neuroblastoma [J].
Fransson, Susanne ;
Abel, Frida ;
Kogner, Per ;
Martinsson, Tommy ;
Ejeskar, Katarina .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 42 (02) :609-616
[30]   Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway [J].
Burris, Howard A., III .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) :829-842